search
Back to results

Autologous Fat Grafting in the Treatment of Critical Limb Ischaemia

Primary Purpose

Critical Limb Ischemia, Peripheral Arterial Disease - PAD, Ischemic Ulcer

Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Autologous Fat Grafting
Sponsored by
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Critical Limb Ischemia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age > 18
  • Established diagnosis of CLI according to TransAtlantic InterSociety Consensus (TASC II) guidelines
  • Ankle oxygen partial pressure < 40 mmHg with no ischaemic lesions or < 60 mmHg with ischaemic lesions
  • Tibial injections site free from ulcers
  • Absence of comorbidities responsible for life expectancy < 6 months
  • Non suitability for surgery (comorbidities or angiographic results)
  • Informed consent taken

Exclusion Criteria:

  • Age < 18 years
  • Inability of understanding and signing informed consent
  • Tibial injections sites involved by ulcers
  • Life expectancy < 6 months
  • Unwillingness to attend follow up
  • Any of the following: women who are or may be pregnant or women hoping to become pregnant; women who are breastfeeding; men whose partners hope to become pregnant during the treatment period

Sites / Locations

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore di MilanoRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Patients with critic limb ischemia

Arm Description

Patient enrolled from emergency room or outpatient population undergo pre-operatory tests including blood test, thoracic radiography, electrocardiogram, cardiologic visit, TcPO2 measurement and Doppler ultrasonography. During surgery the terminal branches of the patient's leg arteries are mapped and under local anesthesia multiple injections (1 mL each) of the adipose tissue formulation are inoculated 1 cm above the end of the terminal branch of the peroneal, anterior, and posterior tibial arteries. Furthermore, a total amount of 0.5-1 ml of the autologous adipose tissue-derived cell (ATDC) fraction is injected 1 cm near to ischaemic lesions. After the surgical procedure, the patient will be followed for 6 months, during which he will undergo outpatient visits at 7 and 21 days; then at 1, 3 and 6 months. At each visit, the patient will be assessed for the amount of pain, the transcutaneous oximetry value, measurement of the ABI index, arterial ultrasound Doppler lower limbs.

Outcomes

Primary Outcome Measures

Pain reduction
Primary endpoint is pain change or complete disappearance, according to Numeric Rating Scale (NRS) ranging from 0 (no pain) ad 10 (maximum amount of pain), ad TcPO2 improvement. The investigators will consider significative a pain change below NRS<4 and a improvement in TcPO2 (> 40 mmHg in patients with rest pain and no ischaemic lesions or > 60 mmHg in patients with rest pain and ischaemic lesions) among at least 70% (14) of the patients enrolled in the study.

Secondary Outcome Measures

Limb salvage
Secondary endpoint is a change in limb salvage rate > 50%, compared to Literature. Literature suggests that a year after the onset of CLI, only about half the patients will be alive without a major amputation, although some of these may still have rest pain, gangrene or ulcers. Approximately 25% will have died and 25% will have required a major amputation. Again, in contrast to patient with intermittent claudication, patients with CLI are on a rapidly downward course in term of both life and their prognosis is in many ways similar to that of some malignant forms of cancer.

Full Information

First Posted
February 3, 2021
Last Updated
February 6, 2021
Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
search

1. Study Identification

Unique Protocol Identification Number
NCT04746599
Brief Title
Autologous Fat Grafting in the Treatment of Critical Limb Ischaemia
Official Title
Autologous Fat Grafting in the Treatment of Critical Limb Ischaemia Non Suitable for Revascularization: The Adipose Tissue - Critical Limb Ischaemia (ADIPOCLI) Trial Protocol
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Unknown status
Study Start Date
January 1, 2021 (Actual)
Primary Completion Date
June 30, 2022 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Critical Limb Ischaemia (CLI) is a condition characterized by chronic ischemic at-rest pain, ulcers, or gangrene for more than 2 weeks in one or both legs, attributable to objectively proven arterial occlusive disease.CLI is associated with a high risk of lower amputation, diminished quality of life and mortality. Revascularization by either bypass surgery or endovascular recanalization is considered the first-choice treatment in patients with CLI. Revascularization is not always possible because patients with CLI often have severe comorbidities or because it is not technically feasible. On the basis of their well-recognized regenerative and angiogenetic properties, cell therapy with autologous bone marrow-derived mesenchymal stem cells (BMMSCs) has been proposed and tested in different animal models and in some human pathological conditions characterized by peripheral ischemia and wound formation.
Detailed Description
The ADIPOCLI trial is an interventional monocentric trial in which the investigators will evaluate the safety, feasibility and potential efficacy of local administration of autologous adipose derived stromal/stem (ASCs) cell as treatment for pain and ulcers caused by CLI. If the results confirm safety, feasibility and show potential beneficial effects of the intervention regarding clinical parameters, a larger clinical research with longer follow up will be initiated focusing on efficacy. The objective of this clinical trial is to assess the efficacy and safety of ASCs inoculation in peri-tibial area, though reducing pain significantly in patients with CLI not eligible for revascularization. Autologous fat grafting is widely used for soft-tissue augmentation and replacement in reconstructive and aesthetic surgery providing a biocompatible, natural and inexpensive method. Noteworthy, recent reports have identified adipose tissue as the tissue in the body that contains the highest percentage of adult stem cells. These adipose derived stem cells (ADSCs) can undergo multilineage differentiation and may be crucial for the surgery purpose of healing ulcers as they have potent regenerative effects on endothelium and immunomodulatory properties. Adipose-derived stromal/stem cells (ASCs) are considered to be an attractive alternative to pluripotent cells with characteristics similar to BMMSCs. Compared with these latter cells, ASCs offer several advantages, including ease of isolation, less donor morbidity, relative abundance, and rapidity of expansion. Preliminary attempts with ASC cell therapy have been made to induce healing of ulcers developed in peripheral vascular diseases of some animal models and human disorders. The benefits of peritibial inoculation of autologous adipose tissue are the reduction of ischemic pain, the improvement of skin and muscle perfusion, the suspension of major amputation interventions and the healing of trophic lesions if present. The result of the intervention varies from individual to individual and depends on the engraftment of the transplanted material. In some cases the pain completely disappears. In others, the transplanted material may undergo varying degrees of reabsorption (from 50% to 70%) and therefore a new transplant may be necessary after some time (6-12 months). The risks are linked to local complications of the procedure such as edema, ecchymosis, pain in the district of surgical aggression (the extent of these three manifestations varies from patient to patient, but are generally modest), dehiscence, bleeding of the wound, site infection surgical. The study has a total duration of 24 months. The recruitment phase lasts 18 months. After the surgical procedure, the patient will be followed for 6 months, during which he will undergo outpatient visits at 7 and 21 days; then at 1, 3, and 6 months. At each visit, the patient will be assessed for the amount of pain and the transcutaneous oximetry value. As in the usual clinical practice and in the diagnostic-therapeutic path of the arteriopathic patient, instrumental examinations (measurement of the ankle-brachial pressure index - ABI, arterial ultrasound Doppler lower limbs) are performed at the enrollment, at the twenty-first day and 6 months after the procedure . The investigators will include 20 patients with CLI who satisfy the inclusion criteria. Inclusion and exclusion criteria were designed to select patients with CLI, not suitable for revascularization and who are in reasonable health condition to allow trial participation. Study participants are recruited from our own outpatient population or emergency room. Baseline characteristics are collected during the first visit and include medical examination, ABI and TcPO2 evaluation and Doppler ultrasonography to study the arterial axis of the limb. If CLI is diagnosed, the patient is hospitalized and undergoes an angiography study. Quality of Lyfe test is administered at hospitalization and at follow up. After angiogram, treatment of choice will be selected during the multidisciplinary vascular conference taking the individual condition of patients into account. Patients eligible for revascularization are submitted to open/endovascular surgery. Patient with CLI unsuitable for revascularization continue hospitalization being given best medical therapy, i.e. pain-killer drugs and prostanoids. Only to these class of patients an adjunctive treatment with local fat grafting is proposed. Information sheet is given to every patient after interview with investigators and informed consent is taken before the procedure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Critical Limb Ischemia, Peripheral Arterial Disease - PAD, Ischemic Ulcer, Ischemic Feet, Diabetic Foot, Scleroderma, Systemic, Thrombo Angiitis Obliterans, Ischemic Leg

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Patients with critic limb ischemia
Arm Type
Experimental
Arm Description
Patient enrolled from emergency room or outpatient population undergo pre-operatory tests including blood test, thoracic radiography, electrocardiogram, cardiologic visit, TcPO2 measurement and Doppler ultrasonography. During surgery the terminal branches of the patient's leg arteries are mapped and under local anesthesia multiple injections (1 mL each) of the adipose tissue formulation are inoculated 1 cm above the end of the terminal branch of the peroneal, anterior, and posterior tibial arteries. Furthermore, a total amount of 0.5-1 ml of the autologous adipose tissue-derived cell (ATDC) fraction is injected 1 cm near to ischaemic lesions. After the surgical procedure, the patient will be followed for 6 months, during which he will undergo outpatient visits at 7 and 21 days; then at 1, 3 and 6 months. At each visit, the patient will be assessed for the amount of pain, the transcutaneous oximetry value, measurement of the ABI index, arterial ultrasound Doppler lower limbs.
Intervention Type
Procedure
Intervention Name(s)
Autologous Fat Grafting
Other Intervention Name(s)
adipose tissue transplantation
Intervention Description
The trochanteric area or the periumbilical abdominal region represents the donor sites. Following Coleman's technique and after the administration of modified Klein solution, a skin incision is performed in the selected area. Adipose tissue is harvested and after suture the area is managed with an elastic-compressive dressing, to be kept in place for 5 days to prevent hematoma formation. The adipose tissue is the centrifuged at 920 × g for 3 min in sterile conditions. Only the intermediate layer containing adipocytes and stromal vascular component will be then injected using a blunt cannula. The terminal branches of the patient's leg arteries are mapped to facilitate graft placement. Under local anesthesia multiple injections of the adipose tissue formulation are inoculated 1 cm above the end of the terminal branch of the peroneal, anterior, and posterior tibial arteries.
Primary Outcome Measure Information:
Title
Pain reduction
Description
Primary endpoint is pain change or complete disappearance, according to Numeric Rating Scale (NRS) ranging from 0 (no pain) ad 10 (maximum amount of pain), ad TcPO2 improvement. The investigators will consider significative a pain change below NRS<4 and a improvement in TcPO2 (> 40 mmHg in patients with rest pain and no ischaemic lesions or > 60 mmHg in patients with rest pain and ischaemic lesions) among at least 70% (14) of the patients enrolled in the study.
Time Frame
7 days
Secondary Outcome Measure Information:
Title
Limb salvage
Description
Secondary endpoint is a change in limb salvage rate > 50%, compared to Literature. Literature suggests that a year after the onset of CLI, only about half the patients will be alive without a major amputation, although some of these may still have rest pain, gangrene or ulcers. Approximately 25% will have died and 25% will have required a major amputation. Again, in contrast to patient with intermittent claudication, patients with CLI are on a rapidly downward course in term of both life and their prognosis is in many ways similar to that of some malignant forms of cancer.
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age > 18 Established diagnosis of CLI according to TransAtlantic InterSociety Consensus (TASC II) guidelines Ankle oxygen partial pressure < 40 mmHg with no ischaemic lesions or < 60 mmHg with ischaemic lesions Tibial injections site free from ulcers Absence of comorbidities responsible for life expectancy < 6 months Non suitability for surgery (comorbidities or angiographic results) Informed consent taken Exclusion Criteria: Age < 18 years Inability of understanding and signing informed consent Tibial injections sites involved by ulcers Life expectancy < 6 months Unwillingness to attend follow up Any of the following: women who are or may be pregnant or women hoping to become pregnant; women who are breastfeeding; men whose partners hope to become pregnant during the treatment period
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Silvia Romagnoli, MD
Phone
+390255035492
Email
silvia.romagnoli@policlinico.mi.it
First Name & Middle Initial & Last Name or Official Title & Degree
Alberto Settembrini, MD
Phone
+390255035492
Email
albertomaria.settembrini@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Santi Trimarchi, Prof
Organizational Affiliation
Fondazione IRCCS Cà Granda Ospedale Maggiore
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fondazione IRCCS Ca' Granda Ospedale Maggiore di Milano
City
Milan
ZIP/Postal Code
20121
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Silvia Romagnoli, MD
Phone
+390255035942
Email
silvia.romagnoli@policlinico.mi.it
First Name & Middle Initial & Last Name & Degree
Alberto Settembrini, MD
Phone
+390255035942
Email
albertomaria.settembrini@policlinico.mi.it
First Name & Middle Initial & Last Name & Degree
Santi Trimarchi, Prof.
First Name & Middle Initial & Last Name & Degree
Silvia Romagnoli, MD
First Name & Middle Initial & Last Name & Degree
Alberto Settembrini, MD
First Name & Middle Initial & Last Name & Degree
Maurizio Domanin, Prof.
First Name & Middle Initial & Last Name & Degree
Daniele Bissacco, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Autologous Fat Grafting in the Treatment of Critical Limb Ischaemia

We'll reach out to this number within 24 hrs